Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.

Chang YT, Hernandez D, Alonso S, Gao M, Su M, Ghiaur G, Levis MJ, Jones RJ.

Blood Adv. 2019 Mar 26;3(6):908-916. doi: 10.1182/bloodadvances.2018022921.

PMID:
30898762
2.

Targeting FLT3 mutations in AML: review of current knowledge and evidence.

Daver N, Schlenk RF, Russell NH, Levis MJ.

Leukemia. 2019 Feb;33(2):299-312. doi: 10.1038/s41375-018-0357-9. Epub 2019 Jan 16. Review.

3.

Clinical implications of molecular markers in acute myeloid leukemia.

Kayser S, Levis MJ.

Eur J Haematol. 2019 Jan;102(1):20-35. doi: 10.1111/ejh.13172. Epub 2018 Oct 23. Review.

PMID:
30203623
4.

Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity.

Lau BW, Huh K, Madero-Marroquin R, De Marchi F, Lim Y, Wang Q, Lobo F, Marchionni L, Smith DB, DeZern A, Levis MJ, Aplan PD, Matsui W, Gondek LP.

Oncogene. 2019 Jan;38(5):687-698. doi: 10.1038/s41388-018-0431-9. Epub 2018 Aug 31.

PMID:
30171262
5.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ.

Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.

6.

A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations.

Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, Liu C, Xie Z, Carson AR, McClain V, Stenzel TT, Miller JE.

Blood Adv. 2018 Apr 24;2(8):825-831. doi: 10.1182/bloodadvances.2018015925.

7.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, Levis MJ, Gladstone DE, Huff CA, Swinnen LJ, Matsui WH, Borrello I, Brodsky RA, Jones RJ, Luznik L.

Blood Adv. 2017;1(4):288-292. doi: 10.1182/bloodadvances.2016002766. Epub 2017 Jan 6.

8.

Advances in targeted therapy for acute myeloid leukaemia.

Kayser S, Levis MJ.

Br J Haematol. 2018 Feb;180(4):484-500. doi: 10.1111/bjh.15032. Epub 2017 Nov 28. Review.

9.

Emerging molecular predictive and prognostic factors in acute myeloid leukemia.

McCurdy SR, Levis MJ.

Leuk Lymphoma. 2018 Sep;59(9):2021-2039. doi: 10.1080/10428194.2017.1393669. Epub 2017 Nov 2. Review.

PMID:
29095060
10.

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.

Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA.

Blood Adv. 2017 Jan 24;1(5):331-340. doi: 10.1182/bloodadvances.2016003053.

11.

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.

Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ.

Cancer. 2018 Jan 15;124(2):306-314. doi: 10.1002/cncr.31038. Epub 2017 Sep 28. Erratum in: Cancer. 2018 May 15;124(10 ):2258.

12.

Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

Kayser S, Levis MJ, Schlenk RF.

Expert Rev Clin Pharmacol. 2017 Nov;10(11):1177-1189. doi: 10.1080/17512433.2017.1387051. Epub 2017 Oct 10. Review.

PMID:
28960095
13.

Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.

Bruner JK, Ma HS, Li L, Qin ACR, Rudek MA, Jones RJ, Levis MJ, Pratz KW, Pratilas CA, Small D.

Cancer Res. 2017 Oct 15;77(20):5554-5563. doi: 10.1158/0008-5472.CAN-16-2593. Epub 2017 Sep 18.

14.

Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Norsworthy KJ, DeZern AE, Tsai HL, Hand WA, Varadhan R, Gore SD, Gojo I, Pratz K, Carraway HE, Showel M, McDevitt MA, Gladstone D, Ghiaur G, Prince G, Seung AH, Benani D, Levis MJ, Karp JE, Smith BD.

Leuk Res. 2017 Oct;61:25-32. doi: 10.1016/j.leukres.2017.08.009. Epub 2017 Aug 30. Review.

15.

Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.

Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, Chin CS, Asthana S, Olshen A, Travers KJ, Wang S, Levis MJ, Perl AE, Radich JP, Shah NP.

Blood. 2017 Jul 6;130(1):48-58. doi: 10.1182/blood-2016-04-711820. Epub 2017 May 10.

16.

The Future of Targeting FLT3 Activation in AML.

Leick MB, Levis MJ.

Curr Hematol Malig Rep. 2017 Jun;12(3):153-167. doi: 10.1007/s11899-017-0381-2. Review.

PMID:
28421420
17.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

18.

Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?

Kayser S, Levis MJ.

Int J Hematol Oncol. 2016 Dec;5(4):123-126. doi: 10.2217/ijh-2017-0001. Epub 2017 Feb 24. No abstract available.

19.

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, Jones G, Kjeldsen L, Grunwald MR, Thomas I, Konig H, Levis MJ, Burnett AK.

Blood. 2017 Mar 2;129(9):1143-1154. doi: 10.1182/blood-2016-07-730648. Epub 2016 Nov 21.

20.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, Dezern AE, Huff CA, Borrello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Haematologica. 2017 Feb;102(2):391-400. doi: 10.3324/haematol.2016.144139. Epub 2016 Oct 20.

21.

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.

Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, Gore SD, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE.

Clin Cancer Res. 2017 Feb 15;23(4):899-907. doi: 10.1158/1078-0432.CCR-16-1274. Epub 2016 Aug 22.

22.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

23.

Carotidynia Heralding the Onset of Acute Leukemia.

Sena LA, Ambinder AJ, Moliterno AR, Levis MJ, Hutchings D, Finn MT, Gelber AC.

Am J Med. 2016 Jul;129(7):e43-5. doi: 10.1016/j.amjmed.2016.03.011. Epub 2016 Apr 9. No abstract available.

PMID:
27068855
24.

A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML.

Lin MT, Tseng LH, Dudley JC, Riel S, Tsai H, Zheng G, Pratz KW, Levis MJ, Gocke CD.

Mol Diagn Ther. 2015 Dec;19(6):409-17. doi: 10.1007/s40291-015-0170-3.

25.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Kasamon YL, Bolaños-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, Rosner GL, Brodsky RA, Perica K, Smith BD, Gladstone DE, Swinnen LJ, Showel MM, Matsui WH, Huff CA, Borrello I, Pratz KW, McDevitt MA, Gojo I, Dezern AE, Shanbhag S, Levis MJ, Luznik L, Ambinder RF, Fuchs EJ, Jones RJ.

J Clin Oncol. 2015 Oct 1;33(28):3152-61. doi: 10.1200/JCO.2014.60.4777. Epub 2015 Aug 10.

26.

FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.

Grunwald MR, Levis MJ.

Semin Hematol. 2015 Jul;52(3):193-9. doi: 10.1053/j.seminhematol.2015.03.004. Epub 2015 Mar 17. Review.

PMID:
26111466
27.

Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia.

Emadi A, Sadowska M, Carter-Cooper B, Bhatnagar V, van der Merwe I, Levis MJ, Sausville EA, Lapidus RG.

Leuk Res. 2015 Jul;39(7):719-29. doi: 10.1016/j.leukres.2015.04.002. Epub 2015 Apr 30.

PMID:
25982179
28.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL.

Blood. 2015 May 7;125(19):3024-31. doi: 10.1182/blood-2015-01-623991. Epub 2015 Mar 26.

29.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Blood. 2014 Dec 11;124(25):3817-27. doi: 10.1182/blood-2014-07-587477. Epub 2014 Oct 14.

30.

Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.

Grunwald MR, Tseng LH, Lin MT, Pratz KW, Eshleman JR, Levis MJ, Gocke CD.

Biol Blood Marrow Transplant. 2014 Dec;20(12):1989-95. doi: 10.1016/j.bbmt.2014.08.015. Epub 2014 Aug 23.

31.

FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.

Ma HS, Nguyen B, Duffield AS, Li L, Galanis A, Williams AB, Brown PA, Levis MJ, Leahy DJ, Small D.

Cancer Res. 2014 Sep 15;74(18):5206-17. doi: 10.1158/0008-5472.CAN-14-1028. Epub 2014 Jul 24.

32.

The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.

Wander SA, Levis MJ, Fathi AT.

Ther Adv Hematol. 2014 Jun;5(3):65-77. doi: 10.1177/2040620714532123. Review.

33.

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.

Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, Strickland SA, Jagasia M, Savani BN, Fraser JW, Sadrzadeh H, Rajkhowa T, Ito S, Jain NA, Battiwalla M, Fathi AT, Levis MJ, Barrett AJ, Hourigan CS.

Leukemia. 2014 May;28(5):1167-70. doi: 10.1038/leu.2014.14. Epub 2014 Jan 10. No abstract available.

34.

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Zeidner JF, Karp JE, Blackford AL, Smith BD, Gojo I, Gore SD, Levis MJ, Carraway HE, Greer JM, Ivy SP, Pratz KW, McDevitt MA.

Haematologica. 2014 Apr;99(4):672-8. doi: 10.3324/haematol.2013.097246. Epub 2013 Dec 20.

35.

Tandem duplication PCR: an ultrasensitive assay for the detection of internal tandem duplications of the FLT3 gene.

Lin MT, Tseng LH, Beierl K, Hsieh A, Thiess M, Chase N, Stafford A, Levis MJ, Eshleman JR, Gocke CD.

Diagn Mol Pathol. 2013 Sep;22(3):149-55. doi: 10.1097/PDM.0b013e31828308a1.

36.

FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.

Kayser S, Levis MJ.

Leuk Lymphoma. 2014 Feb;55(2):243-55. doi: 10.3109/10428194.2013.800198. Epub 2013 Jun 5. Review.

37.

FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Grunwald MR, Levis MJ.

Int J Hematol. 2013 Jun;97(6):683-94. doi: 10.1007/s12185-013-1334-8. Epub 2013 Apr 24. Review.

PMID:
23613268
38.

Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH.

Clin Cancer Res. 2012 Dec 15;18(24):6723-31. doi: 10.1158/1078-0432.CCR-12-2442. Epub 2012 Oct 23.

39.

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM.

Haematologica. 2012 Nov;97(11):1736-42. doi: 10.3324/haematol.2012.062539. Epub 2012 Jun 24.

40.

Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.

Zeidan AM, Ricklis RM, Carraway HE, Yun HD, Greer JM, Smith BD, Levis MJ, McDevitt MA, Pratz KW, Showel MM, Gladstone DE, Gore SD, Karp JE.

Br J Haematol. 2012 Jul;158(2):198-207. doi: 10.1111/j.1365-2141.2012.09142.x. Epub 2012 May 18.

41.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP.

Nature. 2012 Apr 15;485(7397):260-3. doi: 10.1038/nature11016.

42.

A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.

Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, Galkin S, Collector MI, Perkins B, Levis MJ, Griffin CA, Sharkis SJ, Borowitz MJ, Karp JE, Jones RJ.

Blood. 2012 Apr 12;119(15):3571-7. doi: 10.1182/blood-2011-06-364182. Epub 2012 Jan 19.

43.

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.

Karp JE, Vener TI, Raponi M, Ritchie EK, Smith BD, Gore SD, Morris LE, Feldman EJ, Greer JM, Malek S, Carraway HE, Ironside V, Galkin S, Levis MJ, McDevitt MA, Roboz GR, Gocke CD, Derecho C, Palma J, Wang Y, Kaufmann SH, Wright JJ, Garret-Mayer E.

Blood. 2012 Jan 5;119(1):55-63. doi: 10.1182/blood-2011-08-370825. Epub 2011 Oct 14.

44.

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M, Moton-Nelson D, Alino K, Levis MJ, Gore SD, Joseph B, Carraway H, McDevitt MA, Bagain L, Mackey K, Briel J, Doyle LA, Wright JJ, Rudek MA.

Blood. 2011 Mar 24;117(12):3302-10. doi: 10.1182/blood-2010-09-310862. Epub 2011 Jan 14.

45.

Will newer tyrosine kinase inhibitors have an impact in AML?

Levis MJ.

Best Pract Res Clin Haematol. 2010 Dec;23(4):489-94. doi: 10.1016/j.beha.2010.09.008. Epub 2010 Nov 5. Review.

46.

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

Pratz KW, Cho E, Levis MJ, Karp JE, Gore SD, McDevitt M, Stine A, Zhao M, Baker SD, Carducci MA, Wright JJ, Rudek MA, Smith BD.

Leukemia. 2010 Aug;24(8):1437-44. doi: 10.1038/leu.2010.132. Epub 2010 Jun 10.

47.

Bench to bedside targeting of FLT3 in acute leukemia.

Pratz KW, Levis MJ.

Curr Drug Targets. 2010 Jul;11(7):781-9. Review.

48.

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bolaños-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ.

Leuk Res. 2010 Jul;34(7):877-82. doi: 10.1016/j.leukres.2009.11.007. Epub 2009 Dec 4.

49.

New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia.

Tiu RV, Gondek LP, O'Keefe CL, Huh J, Sekeres MA, Elson P, McDevitt MA, Wang XF, Levis MJ, Karp JE, Advani AS, Maciejewski JP.

J Clin Oncol. 2009 Nov 1;27(31):5219-26. doi: 10.1200/JCO.2009.21.9840. Epub 2009 Sep 21.

50.

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore SD, Levis MJ, Wright JJ, Garrett-Mayer E, Kaufmann SH.

Blood. 2009 May 14;113(20):4841-52. doi: 10.1182/blood-2008-08-172726. Epub 2008 Dec 24.

Supplemental Content

Loading ...
Support Center